US FDA approves OTC switch for Prevacid
This article was originally published in Scrip
Executive Summary
Novartis will begin selling an over-the-counter version of Takeda's proton pump inhibitor Prevacid (lansoprazole delayed-release) later this year now that the US FDA has approved an Rx-to-OTC switch application for the 15mg dose.